INTENSITY THERAPEUTICS, INC.INTS

INTENSITY THERAPEUTICS, INC. Segments Disclosure

10-KFiled Mar 27, 20262 min read
Segments
The Company has a single segment and allocates resources based on cash resources and operating expense projections. The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2025 and 2024:

Years Ended December 31,
20252024
Research and development expenses:
Clinical trial expenses:
IT-01 Study (Phase 1/2 Metastatic Cancers)(a)
$— $(128)
INVINCIBLE-2 Study (Phase 2 Breast)(a)
— 233 
INVINCIBLE-3 Study (Phase 3 Sarcoma)(b)
3,806 6,225 
INVINCIBLE-4 Study (Phase 2 Breast)(c)
461 524 
Other clinical trial expenses18 223 
Clinical trial expenses4,285 7,077 
Contract manufacturing71 657 
Salaries and benefits related1,521 1,379 
Consulting & Other(d)
135 143 
Stock-based compensation773 1,240 
Research and development expenses6,785 10,496 
General and administrative expenses:
Salaries and benefits related1,417 884 
Legal fees451 728 
Audit fees310 349 
Consulting609 768 
Insurance670 874 
Other(e)
503 653 
Stock-based compensation1,227 1,833 
General and administrative expenses5,187 6,089 
Loss from operations(11,972)(16,585)
Other segment items, net(f)
366 317 
Net loss$(11,606)$(16,268)
(a)Completed study.
(b)In March 2025, the Company paused new site activations and patient enrollments due to funding constraints.
(c)In September 2025, the Company paused new patient enrollment to revise the dosing regimen for patients receiving INT230-6.
(d)Consulting & Other includes research and development consulting costs and travel-related costs.
(e)Other includes facility expenses, office supplies, computer and software related costs, public relations costs, and travel-related costs.
(f)Other segment items include interest income, interest expense, and foreign exchange gains and losses.
Free Sentinel

Want the next INTENSITY THERAPEUTICS, INC. segments disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment INTENSITY THERAPEUTICS, INC.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

Historical Timeline

Fiscal YearFiled
2025Mar 27, 2026Showing above
2024Mar 13, 2025

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesLeasesDebtNew StandardsPay vs Performance